Location History:
- Ayer, MA (US) (2007)
- Clarks Summit, PA (US) (2009)
- Costa Mesa, CA (US) (2012)
- Los Osos, CA (US) (2019)
- Pennington, NJ (US) (2009 - 2022)
Company Filing History:
2 out of 850 
2 out of 2,405 
1 out of 5,450 
Years Active: 2007-2022
Title: The Innovations of Mark David Ayers: Pioneering Gene Signature Biomarkers
Introduction
Mark David Ayers, based in Pennington, NJ, is an accomplished inventor known for his significant contributions to the field of oncology through his innovative research in gene signature biomarkers. With an impressive portfolio of five patents, Ayers has made remarkable strides in developing methods that can enhance the effectiveness of cancer therapies, particularly those involving PD-1 antagonists.
Latest Patents
Ayers' latest patents have revolutionized the way medical professionals understand and treat cancer. One notable patent is titled "System and methods for deriving gene signature biomarkers of response to PD-1 antagonists." This patent introduces a gene expression platform that comprises a combination of genes correlated with patient response to PD-1 antagonists across various tumor types. Additionally, it presents a normalization gene set and outlines methods for deriving gene signature biomarkers that predict anti-tumor responses to these treatments.
Another significant innovation from Ayers is the patent on "Blood-based biomarkers of tumor sensitivity to PD-1 antagonists." This disclosure focuses on developing baseline and on-treatment blood-based gene signature biomarkers that predict tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers include a PD-L1 gene signature or an interferon gamma gene signature, while the baseline signature involves genes tied to the oxidative phosphorylation pathway. This patent also includes methods and kits for testing tumor samples for these biomarkers, along with treatment strategies based on the test results.
Career Highlights
Throughout his career, Mark David Ayers has held prominent roles in renowned companies such as Millennium Pharmaceuticals Limited and Merck Sharp & Dohme Corporation. His work has led to groundbreaking advancements in cancer treatment strategies, particularly in elucidating the complexities of tumor biology and therapy responses.
Collaborations
Ayers has collaborated with notable professionals in the field, including Andrey Loboda and Jared K Lunceford, whose collective expertise has supported advancements in cancer research and the development of innovative therapies. These collaborations demonstrate the importance of teamwork in the pursuit of medical breakthroughs.
Conclusion
Mark David Ayers stands out as a visionary inventor whose work in developing gene signature biomarkers has significant implications for cancer treatment. His patents and innovations continue to shape the landscape of oncology, offering hope for more effective therapeutic strategies that can enhance patient outcomes. Through his dedication and collaborative efforts, Ayers contributes to the innovative advancements that are crucial in the fight against cancer.